KR102934740B1 - 암 진단 및 치료를 위한 새로운 psma 특이적 결합 단백질 - Google Patents

암 진단 및 치료를 위한 새로운 psma 특이적 결합 단백질

Info

Publication number
KR102934740B1
KR102934740B1 KR1020217036594A KR20217036594A KR102934740B1 KR 102934740 B1 KR102934740 B1 KR 102934740B1 KR 1020217036594 A KR1020217036594 A KR 1020217036594A KR 20217036594 A KR20217036594 A KR 20217036594A KR 102934740 B1 KR102934740 B1 KR 102934740B1
Authority
KR
South Korea
Prior art keywords
ala
leu
ile
thr
pro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020217036594A
Other languages
English (en)
Korean (ko)
Other versions
KR20210150535A (ko
Inventor
에바 보세-되네케
만야 글로저-브로이니히
플로리안 제텔레
에릭 피들러
울리히 하우프츠
Original Assignee
나피고 프로타인스 게엠베하
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 나피고 프로타인스 게엠베하 filed Critical 나피고 프로타인스 게엠베하
Publication of KR20210150535A publication Critical patent/KR20210150535A/ko
Application granted granted Critical
Publication of KR102934740B1 publication Critical patent/KR102934740B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020217036594A 2019-04-10 2020-04-08 암 진단 및 치료를 위한 새로운 psma 특이적 결합 단백질 Active KR102934740B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19168525.4 2019-04-10
EP19168525 2019-04-10
PCT/EP2020/060043 WO2020208083A1 (en) 2019-04-10 2020-04-08 Novel psma specific binding proteins for cancer diagnosis and treatment

Publications (2)

Publication Number Publication Date
KR20210150535A KR20210150535A (ko) 2021-12-10
KR102934740B1 true KR102934740B1 (ko) 2026-03-04

Family

ID=66286079

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020217036594A Active KR102934740B1 (ko) 2019-04-10 2020-04-08 암 진단 및 치료를 위한 새로운 psma 특이적 결합 단백질

Country Status (12)

Country Link
US (1) US12611441B2 (enExample)
EP (2) EP4108680B1 (enExample)
JP (1) JP7498971B2 (enExample)
KR (1) KR102934740B1 (enExample)
CN (1) CN113677698B (enExample)
AU (1) AU2020271959B2 (enExample)
BR (1) BR112021017863A2 (enExample)
CA (1) CA3136229A1 (enExample)
IL (1) IL286791A (enExample)
SG (1) SG11202110940YA (enExample)
WO (1) WO2020208083A1 (enExample)
ZA (1) ZA202108843B (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023285164A1 (en) * 2021-07-13 2023-01-19 Navigo Proteins Gmbh Affinity ligands for the purification and detection of ubiquitin muteins
CN114569744A (zh) * 2022-03-08 2022-06-03 安徽淮仁堂药业股份有限公司 一种锝前列腺标特异性膜抗原显像剂试剂盒及其制备方法和应用
CN116041435B (zh) * 2023-02-21 2023-07-07 浙江农林大学 一种具有2019新型冠状病毒主蛋白酶抑制活性的榛仁蛋白衍生肽及其应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006028429A2 (en) 2002-08-05 2006-03-16 The Johns Hopkins University Peptides for targeting the prostate specific membrane antigen
WO2017149002A1 (en) 2016-03-03 2017-09-08 Navigo Proteins Gmbh Novel fusion proteins for capturing of cells

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003035839A2 (en) * 2001-10-24 2003-05-01 Dgi Biotechnologies, Inc. Target specific screening andits use for identifying target binders
DE10324447A1 (de) * 2003-05-28 2004-12-30 Scil Proteins Gmbh Generierung künstlicher Bindungsproteine auf der Grundlage von Ubiquitin
BR112012014417B1 (pt) 2009-12-14 2021-11-09 Scil Proteins Gmbh Proteínas ubiquitinas modificadas tendo uma atividade de ligação específica para o extradomínio b de fibronectina
WO2012171541A1 (en) 2011-06-15 2012-12-20 Scil Proteins Gmbh Human fusion proteins comprising interferons and hetero-dimeric modified ubiquitin proteins
EP3253785B1 (en) * 2015-02-06 2019-04-10 Navigo Proteins Gmbh Novel egfr binding proteins
US20180030140A1 (en) 2015-02-06 2018-02-01 Navigo Proteins Gmbh Novel binding proteins comprising a ubiquitin mutein and antibodies or antibody fragments
JP7366518B2 (ja) * 2015-05-06 2023-10-23 ヤンセン バイオテツク，インコーポレーテツド 前立腺特異的膜抗原結合フィブロネクチンｉｉｉ型ドメイン
CN107849147B (zh) * 2015-07-20 2021-09-17 纳维格蛋白质有限公司 基于二泛素突变蛋白的Her2结合蛋白
JP2018520675A (ja) * 2015-07-20 2018-08-02 ナフィゴ プロテインズ ゲゼルシャフト ミット ベシュレンクテル ハフツングＮａｖｉｇｏ Ｐｒｏｔｅｉｎｓ ＧｍｂＨ ジユビキチン変異タンパク質をベースとした新規結合タンパク質及びその生成方法
WO2023285164A1 (en) * 2021-07-13 2023-01-19 Navigo Proteins Gmbh Affinity ligands for the purification and detection of ubiquitin muteins

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006028429A2 (en) 2002-08-05 2006-03-16 The Johns Hopkins University Peptides for targeting the prostate specific membrane antigen
WO2017149002A1 (en) 2016-03-03 2017-09-08 Navigo Proteins Gmbh Novel fusion proteins for capturing of cells

Also Published As

Publication number Publication date
EP3953375C0 (en) 2023-06-07
AU2020271959A1 (en) 2021-09-16
EP4108680B1 (en) 2024-05-01
CN113677698B (zh) 2025-02-25
WO2020208083A1 (en) 2020-10-15
JP7498971B2 (ja) 2024-06-13
JP2022528053A (ja) 2022-06-08
ZA202108843B (en) 2023-07-26
BR112021017863A2 (pt) 2022-01-04
AU2020271959B2 (en) 2022-09-29
SG11202110940YA (en) 2021-10-28
EP3953375A1 (en) 2022-02-16
IL286791A (en) 2021-10-31
EP4108680A1 (en) 2022-12-28
CA3136229A1 (en) 2020-10-15
US12611441B2 (en) 2026-04-28
US20220168386A1 (en) 2022-06-02
EP3953375B1 (en) 2023-06-07
KR20210150535A (ko) 2021-12-10
EP3953375B9 (en) 2023-10-04
CN113677698A (zh) 2021-11-19
EP4108680C0 (en) 2024-05-01

Similar Documents

Publication Publication Date Title
AU2016295024B2 (en) Her2 binding proteins based on di-ubiquitin muteins
JP7608538B2 (ja) 癌の診断および治療のための新規なｆｏｌｒ１特異的結合タンパク質
US12611441B2 (en) PSMA specific binding proteins for cancer diagnosis and treatment
JP2026031936A (ja) 線維芽細胞活性化タンパク質（ｆａｐ）のための特異的結合性分子
WO2022223790A1 (en) Novel human programmed death ligand 1 (pd-l1) specific binding molecules
JP2025525305A (ja) 半減期延長ドメインを有する融合タンパク質
EP3325514B1 (en) Her2 binding proteins based on di-ubiquitin muteins
CN118317972A (zh) 成纤维细胞活化蛋白（fap）的特异性结合分子

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

D22 Grant of ip right intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D22-EXM-PE0701 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

F11 Ip right granted following substantive examination

Free format text: ST27 STATUS EVENT CODE: A-2-4-F10-F11-EXM-PR0701 (AS PROVIDED BY THE NATIONAL OFFICE)

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

U12 Designation fee paid

Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U12-OTH-PR1002 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

Q13 Ip right document published

Free format text: ST27 STATUS EVENT CODE: A-4-4-Q10-Q13-NAP-PG1601 (AS PROVIDED BY THE NATIONAL OFFICE)